News Center

10/27

2020

Haihe Biopharma and 3DMed Reached Collaboration for Innovative Analgesics

Shanghai, October 27, 2020-- Haihe Biopharma Co., Ltd. , a leading biotech company focusing on the discovery and development of innovative oncology drugs, and 3D Medicines (Shanghai) Co., Ltd. (hereinafter referred to as “3DMed”) announced today that the two sides have reached a licensing agreement on Haihe Biopharma’s two new analgesics, RMX1001 and RMX1002. 3DMed may carry out the R&D, manufacture and commercialization of RMX1001 and RMX1002 in China. License in of the two innovative analgesic drugs is 3DMed’s important change aiming at the future trend of the chronic disease treatment of tumor. This move will help 3DMed to form a highly synergistic and mutually promoting pipeline layout gradually.

Dr. Ruiping Dong, CEO of Haihe Biopharma, said: 
"We are very pleased to cooperate with 3DMed again. RMX1001 and RMX1002 target upstream and downstream targets in the same pathway, while improving safety and showing strong analgesic characteristics. We look forward to patient’s better treatment options provided by these two products in the field of non-opioid analgesia."
 
Dr. Zhaolong Gong, CEO of 3D Med, commented:
"3DMed is very glad to work with Haihe again. As a new generation of non-opioid analgesics with fewer side effects and better efficacy, we believe that RMX1001 and RMX1002 can relieve pain for patients and bring better quality of life. This is highly consistent with the company's philosophy: commitment to let cancer patients live longer and better.”
 
About RMX1001 and RMX1002

RMX1001 is a new-generation Cox-2 inhibitor. Compared with traditional non-steroidal anti-inflammatory drugs, RMX1001 has better safety, tolerability and significant analgesic characteristics. RMX1002 is an EP4 receptor antagonist. It’s safe, fast onset, and showed sustained analgesic effects. Both drugs have the potential to replace traditional non-steroidal anti-inflammatory drugs as new analgesics.

 

Prior to this, Haihe Biopharma’s subsidiary RMX Biopharma in-licensed the China rights for the development, manufacture and commercialization of two drugs from AskAt Inc. in Japan and completed phase I clinical studies in China. Next, 3DMed will steadily advance the clinical development, and strive to achieve the earlier launch of two new analgesics to help patients reduce pain and improve their quality of life.

About Haihe Biopharma

Haihe Biopharma focuses on discovery, development and commercialization of innovative anti-tumor drugs. Guided by our mission, "Inclusive and open to diversity, innovation oriented to win together and benefit the mankind", Haihe Biopharma insists on the way of independent innovation and pursues global development of China originated innovative drugs. The company is led by an academician of the Chinese Academy of Engineering. The senior management team has extensive experiences in drug research and development in China and abroad. Haihe Biopharma has built a precision medical platform guided by biomarkers, and established a fully integrated pre-clinical evaluation technical platform and clinical study system for innovative drugs, with advanced technology and operation in consistence with international standards and norms, covering subunits from compound synthesis, CMC study, biomarker discovery and validation, medical strategy and clinical study, etc. The company has established a globally competitive innovative drug R&D system and robust product pipeline. There are 7 compounds in clinical and 3 compounds in preclinical studies. 

Please visit the company website for more information: http://www.haihepharma.com

About 3DMed

3DMed is a biomedical company in the stage of advanced clinical development and early commercialization. Adhering to the concept of “helping cancer patients live longer and better”, it focuses on the future trend of chronic disease treatment of tumor and developing a new generation of differentiated immunotherapy drugs to extend the cancer patients’ survival time and improve their quality of life. The company's pipeline includes a new generation of antibodies and small molecule anti-cancer drugs. It has a experienced team with international new drug R&D, registration and commercial operation capabilities.

Please visit the company website for more information: http://www.3d-medicines.com

Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1